4DMT Announces New Employment Inducement Grants

The employee awards comprise options on 260,000 common shares and 157,600 restricted stock units.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

4D Molecular Therapeutics (FDMT) granted equity inducement awards to 13 new non-executive employees on October 13, 2026.

The awards comprise options to purchase 260,000 common shares and 157,600 restricted stock units (RSUs). Each option has a $12.36 exercise price, equal to the closing trading price on the grant date. The compensation committee approved the grants under the amended 2025 Employment Inducement Award Plan and Nasdaq Rule 5635(c)(4) to induce new employees to join the company.

Positive

None.

Negative

Minor point260,000 stock options at a $12.36 exercise price create potential dilution for existing shareholders.
Minor point157,600 restricted stock units granted to new employees create potential shareholder dilution.

Key Figures

Employees receiving grants: 13 employees Stock options: 260,000 shares Restricted stock units: 157,600 RSUs +1 more

Employees receiving grants: 13 employees; New non-executive employees
Stock options: 260,000 shares; Aggregate options granted
Restricted stock units: 157,600 RSUs; Aggregate RSUs granted
Option exercise price: $12.36 per share; Closing trading price on the grant date

Key Terms

restricted stock units (rsus)

1 terms

restricted stock units (rsus) financial

"and 157,600 Restricted Stock Units (RSUs)."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/16/2026 - 04:05 PM EDT

EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 13, 2026, the compensation committee of the Company’s board of directors granted 13 new non-executive employees options to purchase an aggregate of 260,000 shares of the Company’s common stock and 157,600 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $12.36, which was the closing trading price on October 13, 2026, the date of grant. The stock options and RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did 4D Molecular Therapeutics grant to new employees?

4D Molecular Therapeutics granted 13 new non-executive employees options to purchase 260,000 common shares and 157,600 restricted stock units on October 13, 2026. The options have an exercise price of $12.36 per share, matching the closing trading price that day.

4DMT Announces New Employment Inducement Grants